Radius Recycling, Inc. - RDUS STOCK NEWS

Radius Health announced the initiation of the SCOUT-015 pivotal study for RAD011, a synthetic cannabidiol solution targeting hyperphagia in Prader-Willi Syndrome (PWS), affecting 20,000-30,000 patients in the US. The trial, currently featuring 9 active US sites, aims for over 30 global locations and includes multiple dose assessments. RAD011 has received Orphan Drug Designation and Fast Track status from the FDA. Presentations about SCOUT-015 are planned at upcoming conferences. Radius continues to seek patient recruitment to advance this critical clinical trial.

Velan Capital and Repertoire Partners, significant shareholders of Radius Health (RDUS) owning 7.7% of shares, have commented on Gurnet Point Capital and Patient Square Capital's proposed acquisition of Radius valued at $890 million. They express satisfaction that others see untapped value in Radius but highlight concerns over the fairness of the offer. The group advocates for the election of their director nominees, emphasizing their potential to contribute valuable insights whether Radius remains independent or proceeds with the acquisition.

Radius Health, Inc. (Nasdaq: RDUS) has entered into a definitive agreement to be acquired by Gurnet Point Capital and Patient Square Capital for approximately $890 million. The transaction offers Radius shareholders $10.00 per share in cash, plus a potential $1.00 contingent value right (CVR) based on TYMLOS® sales reaching $300 million over a specified period. This acquisition represents a 45% premium over the 30-day average stock price and has been unanimously approved by Radius's board, aiming to maximize shareholder value.

Radius Health and Menarini have submitted a New Drug Application (NDA) to the FDA for elacestrant, an investigational oral SERD for treating ER+/HER2- advanced breast cancer. The submission includes a request for Priority Review, which could lead to an 8-month review timeline. The NDA is based on positive results from the EMERALD study, which demonstrated significant efficacy in patients, including those with ESR1 mutations. Menarini plans to manage commercialization in the U.S. via its subsidiary, Stemline Therapeutics.

Velan Capital and Repertoire Partners, major stockholders of Radius Health (RDUS), advocate for a board reconstitution ahead of the July 8, 2022 Annual Meeting. They cite a 60% employee turnover and a 10% decline in net sales since CEO Martin's tenure began. The current board's governance has led to persistent value destruction, with Radius' stock price down 59% over the past year. Velan-Repertoire urges stockholders to vote for their nominees, citing significant upside potential and promising a roadmap to generate over $100 million in annual Adjusted EBITDA.

Rubric Capital Management, holding 14.62% of Radius Health (NASDAQ: RDUS), announced plans to support Velan-Repertoire's director candidates at the upcoming annual meeting on July 8, 2022. The investment firm expressed concerns over Radius's corporate governance and management's ability to enhance shareholder value. Key initiatives proposed include maximizing the value of Tymlos and elacestrant royalty, generating cash flows from tax attributes, and empowering a top-tier management team. Rubric believes that Radius shares could see an upside of 80%-135% based on a comprehensive evaluation of its assets.

Velan-Repertoire, a prominent stockholder of Radius Health (NASDAQ: RDUS), highlights serious governance issues within the company, including a 49% stock price decline and 60% employee turnover during CEO G. Kelly Martin's leadership. Despite claims of 'internal activism,' the Board's lack of oversight and prioritization of personal interests over stockholder value is emphasized. The group advocates for change by promoting their nominees, including Eric Ende, Cynthia Flowers, and Ann MacDougall, who have proven track records of enhancing stockholder value.

Radius Health, Inc. (NASDAQ: RDUS) has announced significant global expansion for its product TYMLOS (abaloparatide) through new agreements with Labatec Pharma SA (Switzerland and MENA), Pharmbio Korea Inc. (South Korea), and Biosidus (Colombia). This adds 13 new countries outside the U.S., joining Japan and Canada. Radius anticipates regulatory approvals in Japan and Canada by the end of 2022, with potential launches in up to four markets in the first half of 2023. The company will receive milestone payments along with cost of goods sold considerations from these agreements.

Velan Capital Investment Management and Repertoire Partners, owning approximately 7.7% of Radius Health, Inc. (RDUS), filed a proxy statement for the election of their nominees, Eric Ende, Cynthia Flowers, and Ann MacDougall, to the Board. They criticize the current Board for value destruction, poor governance, and mismanagement. Velan-Repertoire argues that substantial change is essential to unlock the company's potential and urges shareholders to vote for their nominees at the July 8, 2022 Annual Meeting.